Accord Sees Benefits From Unique Portfolio
EMENA Chief Paul Tredwell Talks About How The Firm Views Its Broad Offering
Executive Summary
With Accord boasting a broad portfolio that encompasses generics, biosimilars, hybrid medicines and specialty products, Paul Tredwell – the firm’s executive vice-president for the Europe, Middle East and North Africa region – explains how this gives the company a unique position in the market.
You may also be interested in...
Generics Bulletin Editor’s Picks For Q2 2023
Looking back over the second quarter of 2023, Generics Bulletin executive editor Dave Wallace picks out highlights from April to June that include strategic updates from some of the off-patent industry’s biggest players, several exclusive interviews, and the build-up to the second wave of biosimilar competition to Humira in the US.
Coherus Delivers With Pegfilgrastim Autoinjector Launch
Amid increasing competition on biosimilar pegfilgrastim in the US, Coherus is looking to bolster its position with the launch of an Udenyca autoinjector presentation, while it awaits approval for a rival to Amgen’s Neulasta Onpro on-body injector device later this year.
Coherus Looks To Galvanize Pegfilgrastim Biosimilar With New Formats
Coherus BioSciences spoke at length about its two marketed biosimilars, referencing Neulasta and Lucentis, during the company’s first-quarter earnings call.